Claims

1. An intrauterine delivery system which comprises a body construction and two reservoirs (1, 2) comprising a core and a membrane encasing the core, the core and membrane consisting of a same or different polymer composition, wherein said reservoirs comprise 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one which is released over a prolonged period of time at a level required for contraception, characterized in that the release rates and times of release from said reservoirs (1,2) are different.

2. The intrauterine delivery system according to claim 1, characterized in that the membrane encasing the core of **reservoir 1** essentially consists of polydimethylsiloxane (PDMS) or an elastomeric mixture of polyethylene oxide block-polydimethylsiloxane (PEO-b-PDMS) and PDMS or an elastomeric mixture of polytrifluoropropylmethylsiloxane (PTFPMS) and PDMS.

3. The intrauterine delivery system according to claim 2, characterized in that the PEO-b-PDMS/PDMS ratio in the membrane of reservoir 1 is in the range of 95/5 – 0/100 (wt%).

4. The intrauterine delivery system according to claim 2, characterized in that the PTFPMS/PDMS ratio in the membrane of reservoir 1 is in the range of 20/80 - 0/100 (wt%).

5. The intrauterine delivery system according to any of the claims 2 to 4, characterized in that the thickness of the membrane encasing the core of reservoir 1 is 0.15 to 0.3 mm.

6. The intrauterine delivery system according to claim 1, characterized in that the core of **reservoir 1** is a tube-like form with an outer diameter of 2.5-3.0 mm, preferably about 2.8 mm, and with a length of 4-16 mm, preferably about 5 mm.

7. The intrauterine delivery system according to claim 1, characterized in that the membrane encasing the core of **reservoir 2** comprises a mixture of polytrifluoropropylmethylsiloxanes (PTFPMS) and PDMS.

8. The intrauterine delivery system according to claim 7, characterized in that the PTFPMS/PDMS ratio in the membrane of reservoir 2 is 100/0 – 10/90, preferably about 80/20 (wt%).

9. The intrauterine delivery system according to claim 7 or 8, characterized in that the thickness of the membrane encasing the core of reservoir 2 is 0.3 to 0.6 mm.

10. The intrauterine delivery system according to claim 1, characterized in that the core of reservoir 2 is a tube-like form with an outer diameter of 2.5-3.0 mm, preferably about 2.8 mm, and with a length of 4-16 mm, preferably about 8 mm.

11. The intrauterine delivery system according to claim 1, characterized in that the membrane material contains silica filler, the content of which is used to further control the release rate.

12. The intrauterine delivery system according to claim 1, characterized in that the membrane consists of more than one layer, which may comprise different membrane materials.

13. The intrauterine delivery system according to claim 1, characterized in that the amount of 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one incorporated in the cores of reservoirs 1 and 2 is 45-55 %, preferably at most 65 %, based on the weight of the core.

14. The intrauterine delivery system according to any of the claims 1 to 13, characterized in that the release rate of 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one from reservoir 1 is 10-200 µg/d, preferably 10-100 µg/d, for a period of at least three months.

15. The intrauterine delivery system according to any of the claims 1 to 13, characterized in that the release rate of 18-methyl-15ß,16ß-methylene-19-nor-20-spirox-4-en-3-one from reservoir 2 is 1-20 µg/d, preferably 1-10 µg/d for a period of at least three years.